Loan & DebtJul 30, 2026, 04:06 PM
Annexon Secures $200M Credit Facility with Oxford Finance
AI Summary
Annexon, Inc. announced a strategic credit facility agreement with Oxford Finance LLC for up to $200 million. The biopharmaceutical company drew an initial $50 million at closing, with an additional $150 million available upon achieving specific milestones and lender approval. This non-dilutive capital is intended to strengthen Annexon's balance sheet and accelerate its growth strategy, particularly in preparation for the potential global commercialization of its drug candidates, vonaprument and tanruprubart.
Key Highlights
- Annexon secured a strategic credit facility agreement for up to $200 million with Oxford Finance LLC.
- An initial $50 million was drawn at closing.
- An additional $100 million is available upon achieving certain registrational program milestones.
- The remaining $50 million is subject to lender approval.
- The non-dilutive capital aims to enhance financial and operational capabilities.
- Funds will support potential global commercialization of vonaprument and tanruprubart.
Price Impact
More from ANNX